Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells

Annals of the New York Academy of Sciences

Volumn 1171, Issue , 2009, Pages 642-648

  Kim, Su Hyeon ^a   Song, Yoo Cheol ^a   Kim, Su Hyeong ^a   Jo, Hoenil ^a   Song, Yong Sang ^a  

^a Seoul National University   (South Korea)

Author keywords

AG1478; Cisplatin; EGFR; Vulvar cancer

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER GROWTH; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; FEMALE; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MONOTHERAPY; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; VULVA CANCER;

EID: 69149086026     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04893.x     Document Type: Conference Paper

References (42)

1. Sturgeon, S.R. et al. 1992. In situ and invasive vulvar cancer incidence trends (1973 to 1987). Am J Obstet. Gynecol. 166 : 1482 1485
2. Ghurani, G.B. M.A. Penalver. 2001. An update on vulvar cancer. Am. J.Obstet. Gynecol. 185 : 294 299.
3. Hacker, N.F. 1999. Radical resection of vulvar malignancies: a paradigm shift in surgical approaches. Curr. Opin. Obstet. Gynecol. 11 : 61 64.
4. Marsden, D.E. N.F. Hacker. 2001. Contemporary management of primary carcinoma of the vulva. Surg. Clin. North Am. 81 : 799 813.
5. Preti, M. et al. 2000. Recurrent squamous cell carcinoma of the vulva: clinicopathologic determinants identifying low risk patients. Cancer 88 : 2869 2876.
6. Maggino, T. et al. 2000. Patterns of recurrence in patients with squamous cell carcinoma of the vulva. A multicenter CTF Study. Cancer 89 : 116 122.
7. Fonseca-Moutinho, J.A. et al. 2000. Vulvar squamous cell carcinoma. Prognostic factors for local recurrence after primary en bloc radical vulvectomy and bilateral groin dissection. J. Reprod. Med. 45 : 672 678.
8. Rouzier, R. et al. 2002. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet. Gynecol. 100 : 1159 1167.
9. Yoshimatsu, K. et al. 2001. Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clin. Cancer Res. 7 : 2669 2674.
10. Howe, L.R. et al. 2001. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer 8 : 97 114.
11. Kulkarni, S. et al. 2001. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res. 7 : 429 434.
12. Lee, T.S. et al. 2007. Increased cyclooxygenase-2 expression associated with inflammatory cellular infiltration in elderly patients with vulvar cancer. Ann. N. Y. Acad. Sci. 1095 : 143 153.
13. Brustmann, H. 2007. Epidermal growth factor receptor is involved in the development of an invasive phenotype in vulvar squamous lesions, but is not related to MIB-1 immunoreactivity. Int. J. Gynecol. Pathol. 26 : 481 489.
14. Johnson, G.A. et al. 1997. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol. Oncol. 65 : 425 429.
15. Kim, S.H. et al. 2004. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target. J. Cancer Res. Clin. Oncol. 130 : 551 560.
16. Ivanov, V.N. T.K. Hei. 2005. Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene 24 : 616 626.
17. Franke, T.F. et al. 2003. PI3K/Akt and apoptosis: size matters. Oncogene 22 : 8983 8998.
18. She, Q.B. et al. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8 : 287 297.
19. Gurumurthy, S. et al. 2005. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell. Biol. 25 : 1146 1141.
20. Goel, S., M. Hidalgo R. Perez-Soler. 2007. EGFR inhibitor-mediated apoptosis in solid tumors. J. Exp. Ther. Oncol. 6 : 305 320.
21. Liu, Y. et al. 2007. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Lett. 248 : 32 40.
22. Nicolle, G. et al. 2006. Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation. Clin. Cancer Res. 12 : 2937 2943.
23. Kyriakis J.M. J. Avruch. 1996. Protein kinase cascades activated by stress and inflammatory cytokines. Bioassays 18 : 756 777.
24. Sanchez-Perez I. R. Perona. 1999. Lack of c-Jun activity increases survival to cisplatin. FEBS Lett. 453 : 151 158.
25. Bacus, S.S. et al. 2001. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20 : 147 155.
26. Molton, S.A. et al. 2003. Selective activation of the c-Jun N-terminal kinase (JNK) pathway fails to elicit Bax activation or apoptosis unless the phosphoinositide 3'-kinase (PI3K) pathway is inhibited. Oncogene 22 : 4690 4701.
27. Nelson, J.M. D.W. Fry. 2001. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem. 276 : 14842 14847.
28. Chen, Y.R. et al. 2006. Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene 25 : 1205 1215.
29. Boulikas, T. M. Vougiouka. 2003. Cisplatin and platinum drugs at the molecular level. (Review). Oncol. Rep. 10 : 1663 1682.
30. Bellati, F. et al. 2005. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol. Oncol. 96 : 227 231.
31. Kelland, L.R. K.S. Tonkin. 1989. In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity. Eur. J. Cancer Clin. Oncol. 25 : 1211 1218.
32. Raitanen, M. et al. 2002. Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro. Int. J. Cancer 100 : 238 243.
33. Rosenberg, B. 1985. Fundamental studies with cisplatin. Cancer 55 : 2303 2316.
34. Roberts, J.J. F. Friedlos. 1987. Quantitative estimation of cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol. Ther. 34 : 215 246.
35. Zanke, B.W. et al. 1996. Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes. J. Biol. Chem. 271 : 29876 29881.
36. Wang, Z. et al. 2006. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance. Cancer Res. 66 : 8870 8877.
37. Pandey, P. et al. 1996. Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms. J. Biol. Chem. 271 : 23775 23779.
38. Benhar, M., D. Engelberg A. Levitzki. 2002. Cisplatin-induced activation of the EGF receptor. Oncogene 21 : 8723 8731.
39. Cui, W. et al. 2000. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol. Carcinog. 29 : 219 228.
40. Wang, X., J.L. Martindale N.J. Holbrook. 2000. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275 : 39435 39443.
41. Yeh, P.Y. et al. 2002. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem. Pharmacol. 63 : 1423 1430.
42. Woessmann, W., X. Chen A. Borkhardt. 2002. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol. 50 : 397 404.